Renal Cell Carcinoma
Bevacizumab, sorafenib, and temsirolimus combinations did not improve progression-free survival in renal cell carcinoma (RCC).
Asymptomatic presentation, T3 low-grade tumors, and negative lymph nodes are associated with better progression-free and overall survival.
Study findings contradict those of previous investigators.
Data suggest that a 7% or 8% cut-off rather than the conventional 30% is a better predictor in patients treated for mRCC.
RCC tumor shrinkage significantly and independently predicted overall survival.
Neoadjuvant sunitinib was linked to primary tumor and thrombus shrinkage, reduced blood loss during surgery, as well as improved cancer-specific survival.
Pathological stage was the only independent factor linked to kidney cancer progression.
The approach was defined as surgical resection with a wide margin or radiotherapy with a biologically effective dose of 140 Gy or greater.
In a study, patients who had the procedure had a better 5-year overall survival rate than those who did not (68% vs. 27%).
New finding may inform treatment decisions.
It is important to assess factors that may put patients at higher risk of metastatic disease, according to researchers.
Current practice of only focusing on tumor samples might adversely affect care.
The risk is particularly elevated for patients who have CKD risk factors, such as hypertension, diabetes, and older age.
Urine aquaporin-1 and perilipin-2 may have utility as biomarkers for diagnosing malignant clear cell or papillary renal cell carcinoma (RCC).
Studies suggest that these cholesterol-lowering drugs can improve treatment of genitourinary cancers and prevent contrast-induced nephropathy.
Patients with these risk factors should be followed up for the rest of their lives, according to the researchers.
In a study of 4,736 patients with metastatic renal cell carcinoma, use of the drugs was associated with a nearly 22% decreased risk of death.
In a study of post-menopausal women, the highest quartile of lycopene intake was associated with a significant 39% decreased risk of renal cell carcinoma versus the lowest quartile.
98% of the renal tumors were controlled at 9 months after treatment.
Nephron-sparing approach is associated with a 56% decreased risk of postoperative end-stage renal disease versus radical surgery.
Low serum albumin levels increase the risk of death in patients undergoing cytoreductive nephrectomy for metastatic renal cell carcinoma.
Acute kidney injury developed in 23% of renal cell carcinoma patients receiving everolimus.
New study links statin use with a 52% improvement in 3-year disease-specific survival.
It preserves kidney function better than radical nephrectomy in patients with small- to medium-sized tumors, study finds.
Meta-analysis reveals a significantly increased risk of kidney stones only in male patients with kidney cancer.
Among surgically-treated renal cell carcinoma patients, diabetics have a 55% and 32% increased risk of cancer-specific and all-cause mortality.
Study shows that tumor flare resulting from discontinuation of sunitinib and pazopanib is associated with decreased overall survival.
Ultrasound surveillance for renal tumors should be performed on native and graft kidneys from 3 years after transplantation.
Are you more likely to perform partial rather than radical nephrectomy for tumors if robotic-assisted surgery is available?September 26, 2014
Availability of robotic-assisted surgery at a hospital was independently associated with greater use of partial nephrectomy.
- New Dyslipidemia Guidelines Eliminate Treatment Targets
- Complications More Likely After Radiotherapy vs. Surgery for PCa
- Cholecalciferol May Be Superior for Treating Vitamin D Deficiency
- Laparoscopically Harvesting Right Kidneys from Living Donors Safe
- Metformin Use in Advanced CKD Raises Death Risk
Sign Up for Free e-newsletters
NEPHROLOGY & UROLOGY NEWS
- Acute Kidney Injury (AKI)
- Chronic Kidney Disease (CKD)
- Contrast Nephropathy
- Cardiovascular Disease (CVD)
- Diabetic Nephropathy
- End-stage Renal Disease (ESRD)
- Lupus Nephritis
- Peritoneal Dialysis
- Secondary Hyperparathyroidism (SHPT)